RVR was found to be the useful predictor for SVR in treatment of CHC with peg-IFN plus ribavirin. With this aspect in mind, we examined the host genotypes associated with different IFN responses. In patients with RVR, CC genotypes at rs12979860 were present in 77% of the patients whereas the unfavourable CT was present in only 23% of the individuals. Interestingly, none of the patients achieving RVR Talatisamine reported unfavourable TT allele at rs12979860. Similarly, at locus rs8099917, response rates were 73.2% TT, 19.2% TG, followed by 7.6% GG allele. Similar results were obtained in patients with SVR which shows that in 83% of the patients achieving SVR had the favourable CC allele at rs12979860. Interestingly, in patients with relapsed infection it was seen that 66% of the patients had unfavourable CT allele at their rs12979860 locus followed by 34% TT allele. Also at rs8099917, TG genotype was present in 72.4% individuals followed by GG host genotype in 27.6% individuals. Therefore, it could be assumed that favourable genotypes at both rs12979860 and rs8099917 could be important markers for the prediction of the favourable results in patients undergoing IFN therapy in genotype 3 infected patients. Within treatment naive HCV infected individuals, our results showed that the percentage of favourable allele rs12979860 CC and rs8099917 TT was higher; therefore it could be assumed that within our study Mycophenolic acid population the propensity to towards favourable alleles is higher and it could be a valuable input for physicians in predicting the treatment response. The limitation of the study was that the number of samples size with patients undergoing IFN treatment was small. A large cohort of patients undergoing IFN therapy is needed to explain in detail how the SNP rs12979860 and rs8099917 could influence the treatment response in HCV genotype 3 infected population. Our results are the first report from this part of the country providing information about the impact of IL28B genotypes in different HCV infected population groups from eastern and northeastern India. Our results for the first time indicate that for HCV genotype 3 infected patients, CC genotype at rs12979860 is an important predictor for patients to achieve RVR. Additionally our results also emphasized the point that rs12979860 CC host genotype was significantly associated with SVR in genotype 3 infected individuals with high viral load. To best of our knowledge, our data on SNP rs8099917 is the first Indian data within HCV infected population to be reported from this region. In conclusion, it could be said that in the current scenario, where the cost of IFN treatment for HCV is very high to the people of our country where the healthcare system is already overburdened with lack of resources. Therefore, it is the need of the hour to shift our focus to how the treatment mechanisms can be tailor-made to suit every individual’s genetic makeup. A common pathology of pregnancies is early abortion, and 75% of early abortions are associated with embryo implantation failure. Embryo survival within the maternal uterus is affected by many factors, among which humoral homeostasis in the uterine cavity plays an important role in maintaining cellular homeostasis, which ultimately affects embryo implantation, differentiation and viability. The early embryo after fertilization appears to have a reduced capacity to regulate homeostasis.